[
  {
    "ts": null,
    "headline": "Esperion Therapeutics: Biotech With Limited Upside, Hold",
    "summary": "Esperion faces pressure from emerging oral PCSK9i and CETP inhibitors, which offer superior LDL-c lowering. See why I rate ESPR stock a Hold.",
    "url": "https://finnhub.io/api/news?id=07e70197847e8f3c8b57e631dc52cc400f43d287b7a5a38da65ad0ea7d483294",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762826788,
      "headline": "Esperion Therapeutics: Biotech With Limited Upside, Hold",
      "id": 137437263,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635084121/image_1635084121.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Esperion faces pressure from emerging oral PCSK9i and CETP inhibitors, which offer superior LDL-c lowering. See why I rate ESPR stock a Hold.",
      "url": "https://finnhub.io/api/news?id=07e70197847e8f3c8b57e631dc52cc400f43d287b7a5a38da65ad0ea7d483294"
    }
  }
]